Presence of hiv-1 r5 viruses in cerebrospinal fluid even in patients harboring r5x4/x4 viruses in plasma

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 1, 2009, Pages 60-64

  Soulié, Cathia ^a,b,c   Tubiana, Roland ^a,b,c   Simon, Anne ^c   Lambert Niclot, Sidonie ^a,b,c   Malet, Isabelle ^a,b,c   Canestri, Ana ^a,b,c   Brunet, Christel ^c   Murphy, Robert ^a,c   Katlama, Christine ^a,b,c   Calvez, Vincent ^a,b,c   Marcelin, Anne Geneviève ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CCR5 antagonist; Cerebrospinal fluid; Compartment; Coreceptor; Tropism

Indexed keywords

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR5; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; PLANT GROWTH; PRIORITY JOURNAL; PROTEINASE INHIBITION;

ADULT; AGED; AIDS DEMENTIA COMPLEX; DRUG RESISTANCE, VIRAL; FEMALE; GENES, ENV; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; YOUNG ADULT;

EID: 67651181012     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819fb903     Document Type: Article

References (29)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
2. Poveda E, Briz V, Quinones-Mateu M, et al. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-1367.
3. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature. 1998;391:240.
4. Albright AV, Shieh JT, Itoh T, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999;73:205-213.
5. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997;385:645-649.
6. Li S, Juarez J, Alali M, et al. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissuederived isolates. J Virol. 1999;73:9741-9755.
7. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
8. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381: 667-673.
9. Gorry PR, Bristol G, Zack JA, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol. 2001; 75:10073-10089.
10. Ohagen A, Ghosh S, He J, et al. Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. J Virol. 1999;73:897-906.
11. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539-1545.
12. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol. 2003;9: 205-221.
13. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31:171-177.
14. Mayer H, Van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviralexperienced subjects infected with dual mixed-tropic HIV-1: 24 week results of phase2b exploratory trial. Paper presented at: IAS; August 13-18, 2006; Toronto, Ontario. Abstract THLB0215.
15. Moore JP, Kitchen SG, Pugach P, et al. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004;20:111-126.
16. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis. 2004;17:7-16.
17. Beerenwinkel N, Sing T, Lengauer T, et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics. 2005;21:3943-3950.
18. Jensen MA, Li FS, van't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003;77:13376-13388.
19. Raymond S, Delobel P, Mavigner M, et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS. 2008;22:F11-F16.
20. Korber BT, Kunstman KJ, Patterson BK, et al. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol. 1994;68:7467-7481.
21. Cunningham PH, Smith DG, Satchell C, et al. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS. 2000;14:1949-1954.
22. Stingele K, Haas J, Zimmermann T, et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology. 2001;56:355-361.
23. Tashima KT, Flanigan TP, Kurpewski J, et al. Discordant human immunodeficiency virus type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma. Clin Infect Dis. 2002;35:82-83.
24. Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191:890-898.
25. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194:926-930.
26. Delobel P, Nugeyre MT, Cazabat M, et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol. 2007; 45:1572-1580.
27. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591-595.
28. SN 01361. Exploratory Nonclinical Pharmacokinetics and Metabolism of SCH 4 17690. Kenilworth, NJ; Schering-Plough: 2002.
29. Napier C, DP, Gladue R, et al. The preclinical pharmacokinetics and safety pharmacology of the anti-HIV CCR5 antagonist, UK-427,857. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, MA.